Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout
Sobi® today announced the initiation of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SEL-212. The submission is based on the results of the DISSOLVE I and II pivotal studies. SEL-212 is an innovative biologic therapy in development for the treatment of chronic refractory gout, a debilitating condition characterised by the persistent and painful buildup of urate crystals in the joints. This significant milestone follows the FDA’s Fast Track designation of SEL-212 in March 2024, underscoring the urgent need for new treatment options
Konecranes has acquired the service business of Dungs Kran- und Anlagentechnik GmbH, a specialist in crane system services based in Voerde, Lower Rhine region in Germany. The value of the purchase is not being disclosed.
With the acquisition, effective from July 1, 2024, Konecranes expands its Germany-wide service network with a competent and experienced team at the new location in Voerde.
Dungs Kran- und Anlagentechnik GmbH specializes in the service, expert consulting and modernization services of crane systems in the western part of Germany. Founded in 1995 and with sales of
